Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene RET
Variant mutant
Impact List unknown
Protein Effect unknown
Gene Variant Descriptions RET mutant indicates an unspecified mutation in the RET gene.
Associated Drug Resistance
Category Variants Paths

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01831726 Phase II Dovitinib Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Completed USA 0
NCT03780517 Phase I DS-5010 Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors Completed USA | FRA | ESP | BEL 3
NCT01896479 FDA approved Cabozantinib A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER) Active, not recruiting NLD | ITA | FRA | ESP | CAN | AUS 8
NCT03391869 Phase III Ipilimumab + Nivolumab Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer Recruiting USA 0
NCT03052569 Expanded access RXDX-105 Expanded Access to RXDX-105 for Cancers With RET Alterations No longer available USA 0
NCT04683250 Phase Ib/II Vepafestinib Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET)) Recruiting USA 1
NCT05502237 Phase III AB154 + Cisplatin + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Nab-paclitaxel AB154 + Carboplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel + Zimberelimab AB154 + Carboplatin + Nab-paclitaxel + Zimberelimab AB154 + Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab AB154 + Cisplatin + Pemetrexed Disodium + Zimberelimab Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 13
NCT03175224 Phase Ib/II Vebreltinib APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) Recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 6
NCT05565417 Phase Ib/II IMT-009 Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT01396408 Phase II Temsirolimus Sunitinib A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Active, not recruiting CAN 0
NCT04760288 Phase III Cabozantinib Pralsetinib Vandetanib A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC) Withdrawn ESP 0
NCT04105270 Phase II Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial Recruiting USA 0
NCT05117242 Phase II GEN1046 + Pembrolizumab GEN1046 Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU 2
NCT03037385 Phase Ib/II Pralsetinib Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL 5
NCT02193152 Phase I Pazopanib Pazopanib in Molecularly Selected Patients With Advanced NSCLC Terminated USA 0
NCT03157128 Phase Ib/II Selpercatinib A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 8
NCT01877811 Phase Ib/II RXDX-105 CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 Completed USA 0
NCT02299141 Phase I Nintedanib Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03934372 Phase Ib/II Ponatinib Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Recruiting NLD | ITA | GBR | FRA | ESP | DEU | BEL 2
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Completed USA | AUS 0
NCT02693535 Phase II Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) Recruiting USA 0
NCT05443126 Phase Ib/II EP0031 A Study of EP0031 in Patients With Advanced RET-altered Malignancies Recruiting USA | GBR | ESP 0